ArticleGastroenterology & hepatology2010
Emerging prognostic markers to determine Crohn's disease natural history and improve management strategies: a review of recent literature.
Article in Gastroenterology & hepatology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 23 citations in OpenAlex.
- Cross-Sectional Imaging Features Associated With Disease Progression in Crohn's Disease.Inflammatory bowel diseases · 2026Article
- Hydroxyethyl starch-curcumin nanoparticles ameliorate DSS-induced ulcerative colitis in mice via synergistic TLR4/NF-κB suppression, Nrf2 activation, intestinal barrier restoration, and gut microbiota modulation.Frontiers in pharmacology · 2025Article
- Article
- IL-10 downregulates CXCR3 expression on Th1 cells and interferes with their migration to intestinal inflammatory sites.Mucosal immunology · 2016Article
- Disease Phenotype, Activity and Clinical Course Prediction Based on C-Reactive Protein Levels at Diagnosis in Patients with Crohn's Disease: Results from the CONNECT Study.Gut and liver · 2016Article
- Quality of care in Crohn's disease.World journal of gastrointestinal pathophysiology · 2014Review
- Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry.The American journal of gastroenterology · 2012Article
- An update of the role of nutritional therapy in the management of Crohn's disease.Journal of gastroenterology · 2012Review
- Combination of genetic and quantitative serological immune markers are associated with complicated Crohn's disease behavior.Inflammatory bowel diseases · 2011Article
- Targeting mucosal healing in Crohn's disease.Gastroenterology & hepatology · 2011Article
- Crohn's disease: the first visit.Gastroenterology & hepatology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Because Crohn's disease (CD) is a chronic, incurable condition, patients require life-long therapeutic approaches to initiate and maintain symptom control, improve quality of life, avoid hospitalizations and surgery, and minimize short- and long-term toxicity and complications such as stricturing, fistulae, osteoporosis and associated bony fractures, and linear growth failure in pediatric patients. Many physicians use symptom-based classifications, such as those published in the American College of Gastroenterology Practice Guidelines, to classify disease severity. However, all current classifications for CD focus predominantly on treating the present symptoms and not on the long-term treatment goal of altering the natural history of the disease. If physicians were able to identify disease phenotypes; at diagnosis, they could advise a course of robust intervention or more. conservative therapeutic modalities with a lower risk of toxicity, as appropriate. Over the past several years, much interest has developed in the role of genetic and serologic markers as prognostic tools in CD. With these genetic and serologic data in mind, clinicians have a growing ability to harness laboratory and genetic testing information in order to stratify patients relative to their risk of disease progression from the time of diagnosis, allowing for a more individualized treatment plan for each patient.
Indexed as
Identifiers
20567551PMC2886456W317578460What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.